Mesoblast Limited ( (AU:MSB) ) has shared an update.
Mesoblast Limited announced the upcoming availability of Ryoncil®, the first FDA-approved mesenchymal stromal cell therapy for pediatric patients with steroid-refractory acute graft versus host disease (SR-aGvHD). This approval marks a significant milestone, providing a life-saving treatment option for children with this high-risk condition, and is expected to positively impact Mesoblast’s market positioning. Additionally, Mesoblast is advancing its product pipeline with plans to evaluate Ryoncil® for other inflammatory diseases and pursuing accelerated approval for its heart failure treatment, Revascor®, highlighting the company’s ongoing commitment to addressing unmet medical needs.
More about Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines, focusing on treatments for inflammatory diseases. The company is known for its innovative use of mesenchymal stromal cells (MSC) in developing therapies for conditions such as steroid-refractory acute graft versus host disease (SR-aGvHD) and chronic heart failure.
YTD Price Performance: 21.82%
Average Trading Volume: 296,508
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.03B
For a thorough assessment of MSB stock, go to TipRanks’ Stock Analysis page.